Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | PHASE2/PHASE3 | RECRUITING | 235 | — | — | Sep 1, 2020 | Feb 1, 2030 | Dec 30, 2025 | - | — |
| Name | Type | Description |
|---|---|---|
| HMPL-453 | DRUG | Cohort\_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort\_2, Cohort\_3 and Cohort\_4:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle) |